ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Epigenetic Silencing of CYYR1 Promotes Lung Adenocarcinoma Progression Through TRIM21-Dependent Regulation of HMMR Stability.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality. Integrative multi-omics and machine-learning analyses across independent cohorts identified CYYR1 as a frequently downregulated transmembrane protein in LUAD, with low expression associated with poor prognosis and promoter hypermethylation. CYYR1 restoration suppressed LUAD cell proliferation, migration, invasion, tumor growth, and metastasis. Mechanistically, CYYR1 facilitated TRIM21-dependent ubiquitination and proteasomal degradation of HMMR, thereby reducing CDC20-associated oncogenic signaling. Biochemical and cellular analyses supported this CYYR1-TRIM21-HMMR regulatory relationship, while a patient-derived LUAD organoid model provided proof-of-concept evidence that CYYR1 restoration inhibited organoid growth and reduced HMMR, CDC20, and Ki67 expression. CYYR1 restoration also increased cisplatin sensitivity. Genistein treatment was associated with CDC20 modulation and enhanced cisplatin response, and cellular thermal shift assays provided evidence consistent with CDC20 engagement, although CDC20 dependence of the Genistein response remains unproven. Collectively, these findings identify CYYR1 as an epigenetically dysregulated tumor-suppressive factor that regulates HMMR stability through a TRIM21-dependent mechanism and reveal a potential therapeutic vulnerability in CYYR1-deficient LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.